Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.
Advanced Solid Tumor
DRUG: IM156
Dose Limiting Toxicity (DLT), Evaluate the safety and tolerability to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), 4 weeks
Maximum plasma concentration (Cmax), 4 weeks|Time to Cmax (Tmax), 4 weeks|Area under the curve (AUC), 4 weeks|Plasma half life (T1/2), 4 weeks|Volume of distribution (V/F), 4 weeks|Plasma Clearance (CL/F), 4 weeks|Exploratory Surrogate Biomarker, Explore potential surrogate biomarkers in peripheral blood mononuclear cells (PBMC)., 2 weeks|Preliminary tumor response, Assess objective tumor response and progression based on the Response Evaluation Criteria for Solid Tumor (RECIST) v1.1 \[for patients with recurrent glioblastoma, the Response Assessment in Neuro-Oncology (RANO) guideline is applied\]., Every 8 weeks up to end of treatment (EOT)
The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.